Search

Your search keyword '"Hayman, Suzanne R."' showing total 2,017 results

Search Constraints

Start Over You searched for: Author "Hayman, Suzanne R." Remove constraint Author: "Hayman, Suzanne R."
2,017 results on '"Hayman, Suzanne R."'

Search Results

1. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

4. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

5. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

7. Muscle and fat composition in patients with newly diagnosed multiple myeloma

8. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

9. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

11. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

13. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma

14. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

15. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy

16. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma

17. Outcomes after biochemical or clinical progression in patients with multiple myeloma

18. Metformin and cytokine release syndrome after immune effector cell therapy.

19. First relapse in patients with multiple myeloma: Outcomes and predictors.

20. Class comparison of BCMA-directed therapies in relapsed multiple myeloma.

21. Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.

22. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

24. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

25. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

26. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma

27. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

29. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma

34. Prognostic restaging after treatment initiation in patients with AL amyloidosis

35. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

36. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients

37. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation

38. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)

39. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities

42. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

43. Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma

44. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation

45. A simple additive staging system for newly diagnosed multiple myeloma

46. Revisiting complete response in light chain amyloidosis

47. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

Catalog

Books, media, physical & digital resources